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Abstract
Background and Aims: Bile analysis has the potential to serve as a surrogate marker for inflammatory and neoplastic
disorders of the biliary epithelium and may provide insight into biliary pathophysiology and possible diagnostic markers.
We aimed to identify biliary protein markers of patients with primary sclerosing cholangitis (PSC) by a proteomic approach.
Methods: Bile duct-derived bile samples were collected from PSC patients (n=45) or patients with choledocholithiasis
(n=24, the control group). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to analyse the
proteins, 2-D-gel patterns were compared by densitometry, and brush cytology specimens were analysed by RT-PCR.
Results: A reference bile-duct bile proteome was established in the control group without signs of inflammation or
maligancy comprising a total of 379 non-redundant biliary proteins; 21% were of unknown function and 24% had been
previously described in serum. In PSC patients, the biliary S100A9 expression was elevated 95-fold (p,0.005), serum protein
expression was decreased, and pancreatic enzyme expression was unchanged compared to controls. The S100A9
expression was 2-fold higher in PSC patients with high disease activity than in those with low activity (p,0.05). The brush
cytology specimens from the PSC patients with high disease activity showed marked inflammatory activity and leukocyte
infiltration compared to the patients with low activity, which correlated with S100A9 mRNA expression (p,0.05).
Conclusions: The bile-duct bile proteome is complex and its analysis might enhance the understanding of cholestatic liver
disease. Biliary S100A9 levels may be a useful marker for PSC activity, and its implication in inflammation and carcinogenesis
warrants further investigation.
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Introduction
Cholestatic liver disease (CLD) is a major cause of liver damage
and failure. CLD pathogenesis ranges from choledocholithiasis,
which is often completely relieved by endoscopic intervention, to
chronic diseases such as primary sclerosing cholangitis (PSC),
which may require liver transplantation [1,2,3] [4]. For some
CLD pathologies (e.g., transporter defects), the underlying
pathological mechanisms have been thoroughly elucidated,
whereas for others, including PSC and post-transplant cholangio-
pathies, the pathophysiological basis of the disease and disease
progression remain much less clear [5]. Some forms of CLD are
complicated by malignancy, specifically cholangiocarcinomas.
Cholangiocarcinomas are associated with a poor prognosis, in
part due to being detected at later stages when resection is no
longer feasible [1,6]. Recent advances in endoscopic retrograde
cholangiography (ERC) and its wide-spread use in treating CLD
have allowed for sampling bile duct-derived bile during routine
examinations [7].
Bile is secreted by hepatocytes into the canaliculi and is then
continuously modified by cholangiocytes. The major constituents
of bile include bile acids (BA) and phospholipids, which are
primarily composed of phosphatidylcholine, and cholesterol. The
lipid components of bile are complemented by proteins,
predominantly mucins [8,9]. Despite bile composition research
having the potential to improve the understanding of PSC
pathogenesis and enhance the development of new cholangiocar-
cinoma biomarkers, little is known about the protein components
of bile. Due to interference between bile contents and proteomic
analysis methods, a comprehensive proteomic analysis of bile duct-
derived bile samples is technically more challenging than similar
comprehensive analyses of other biological fluids, such as plasma,
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protein profiles, but a recent study that compared peptide patterns
using a special mass spectrometry approach demonstrated
expression differences in patients with cholestatic liver disease [10].
In this study, we performed a comprehensive analysis of the bile
duct-derived bile proteome to identify the differences in biliary
protein expression profiles among patients with CLD. We
specifically focused on PSC, with the goals of gaining new insights
into CLD pathophysiology and establishing a strong basis for the
discovery of new diagnostic markers.
Materials and Methods
Patients and Bile Sampling during ERC
Bile-duct sampling was performed in patients undergoing ERC
prior to any therapeutic procedures and after selective intubation of
the papilla. Bile samples were mixed with protease inhibitors
(Complete, EDTA-free, Roche, Germany), snap frozen in liquid
nitrogen, and stored at 280uC until further use. Bile samples from
69 patients were included in this study. 24 of the patients had been
diagnosed with choledocholithiasis, and 45 patients had PSC.
Diagnosis of PSC was made based on typical ERC findings, and all
the PSC patients received ursodeoxycholic acid. The clinical data
are presented in Table 1. None of the patients had a history of
variceal bleeding.TheMayo riskscore(MRS) was calculatedforthe
PSC patients [11], and the endoscopic disease activity in them was
classified as follows: 1) high disease activity: $3 balloon dilatations/
year, $2 episodes of clinical biliary obstruction (i.e., jaundice,
abdominal pain), or progression of biliary tree destruction as
determined by the ERC, and 2) low disease activity: all other PSC
patients. Samples from patients with apparent bacterial and/or
fungal biliary infections were excluded. All procedures in this study
werecompliant with the Declaration of Helsinki and were approved
by a local ethics committee (Ethikkommission der Medizinischen
Fakulta ¨t Heidelberg, Alte Glockengießerei 11/1 D-69115 Heidel-
berg). All patients provided written informed consent.
Sample Preparation, 2D Gel Electrophoresis, and mass
spectrometry
Excess albumin and IgG were removed from bile samples. First,
200 ml of bile was centrifuged for 10 min at 13,000 g to remove
debris. Depending on the protein concentration, 25–100 ml of resin-
coupled antibodies against albumin and IgG (Albumin and IgG
Removal Kit, Amersham Biosciences) was added after washing the
resin with PBS, and incubated for 609. The resin was removed
by centrifugation. To remove lipophilic substances, the following
precipitation protocol was established based on a protocol for plant
protein extraction [12]: 1 ml of 0.1 M ammonium acetate in 100%
methanol was added to 200 ml of bile at 220uC, vortexed and
incubated overnight. The precipitated protein was pelleted at
13,000 g, the supernatant was discarded, the pellet was washed
twice with 1.2 ml 0.8 M ammonium acetate/80% methanol at
220uC, and then the pellet was washed twice with 80% acetone.
The resulting pellet was air dried on ice. Protein concentration was
measures by 2-D-Quant kit (Amersham Biosciences). For the 2-D
SDS-PAGE, the pellets were resuspended in lysis buffer containing
7 M urea, 2 M thiourea (Merck), 2% (w/v) CHAPS, 1% (w/v)
DTT (Sigma), 2% (v/v) Pharmalyte 3–10 (Amersham Biosciences),
and protease inhibitor mixture. The extracts were separated in the
first dimension using 18-cm strips with immobilised non-linear
gradients ranging from pH 3 to 11 (Amersham Biosciences) and in
the second dimension using a standard SDS-PAGE technique
[13,14]. The 2-D gels were stained with either silver or colloidal
Coomassie dye. The procedures were performed under standard-
ised conditions for all the gels. Total BA concentrations were
determined enzymatically using 3alpha- hydroxysteroid dehydro-
genase (Enzabile; Nycomed, Oslo, Norway).
Following SDS-PAGE separation and Coomassie staining, the
proteins were analysed by mass spectrometry. Detailed informa-
tion on the parameters can be found in the supplemental material.
1-D Gel Electrophoresis and total S100 measurement
The protein samples were separated by 1-D SDS-PAGE (Nu-
Page 4–12% Bis-Tris-Gel, Invitrogen Life Technologies, USA)
and stained with either silver or colloidal Coomassie dye. The total
S-100 protein levels were measured using a routine electrochemi-
luminescence assay (ECLIA; Elecsys S-100H assay; RocheH
Diagnostics; Mannheim, Germany).
Cytopathological evaluation and expression analyses
Brush cytology specimens were obtained during ERC in cases of
unclear strictures. All the biliary brushing specimens were initially
Table 1. Patient characteristics.
[median ± SEM] Control PSC PSC low activity PSC high activity PSC low MRS PSC interm. MRS
N2 4 4 5 2 6 1 9 2 5 2 0
F/M 9/15 11/34 7/19 4/15 6/19 5/15
Age [yrs] 5063.7 4261.8 4062.3 5062.9 3862.0 4563.1
Bilirubin [mg/dl] 1.160.5 1.060.3 0.960.08 2.060.5 0.860.08 1.860.5
C-reactive protein 8.4616.2 4.266.7 2.060.6 11.6613.8 2.060.6 11.6613.8
WBC [/nl] 7.060.9 6.260.4 6.960.3 5.060.8 6.260.3 6.960.8
AP [IU/l] 167674 229631 178632 293657 174633 284656
GGT [IU/l] 4156132 112654 109649 1536106 115652 896104
AST [IU/l] 616139 46653 3 646 4 610 33646 3 610
ALT [IU/l] 191666 44610 40610 47619 44611 45618
Albumin 42.361.8 41.060.8 43.860.7 39.761.4 44.060.6 39.361.3
Mayo Risk Score N/A 20.1660.14 20.3460.09 0.9060.19 20.3860.07 0.8160.16
MRS Mayo risk score; PSC low and high activities refer to the endoscopic finding.
doi:10.1371/journal.pone.0029821.t001
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for cytological evaluation: PAP (Papanicolau), HE (hematoxylin
and eosin), and PAS (periodic acid-Schiff). The diagnoses were
made by the pathologist. The remaining brushes were immediately
placed in tubes containing RNAlater (Qiagen, Hilden, Germany).
The S-100A9 mRNA expression levels were analysed using
standard kits (Search-LC, Heidelberg, Germany). The gene
expression was normalised to that of the housekeeping gene
cyclophilin B.
Image Processing, Dataset, and Statistical Analyses
Digitised images of 2-D gels from the series were analysed using
the ImageJ Software (Rasband, W.S., ImageJ, US National
Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.
nih.gov/ij/, 1997–2009) for spot detection, gel matching, and
background correction, and these data were normalised to the sum
of the total spot volume.
Data on protein and gene names, predicted molecular weights,
and pI values were retrieved from UniProt (www.expasy.ch) [15].
Pathways proteins are involved in were analysed by using UniProt
and Genecards databases (www.expasy.ch; www.genecards.com).
All statistical analyses were performed using the PASW 17
software (SPSS Inc., Chicago, Illinois). Non-parametric Mann-
Whitney U test was used for continuous data, and Fisher’s exact
test was used where applicable. All p values ,0.05 were
considered to be statistically significant.
Results
Establishment and improvement of a biliary protein
purification protocol
The bile protein expression profiles in the 1-D SDS-PAGE
separation from the patients with choledocholithiasis were similar
to the serum and plasma profiles from the same patients (Fig. 1A).
Furthermore, the bile samples were found to contain varying
concentrations of albumin, which was the most predominant bile
protein in most of the analysed samples. As high concentrations of
albumin strongly interfere with measurements by masking the
proteins in lower abundance and by limiting the success of
isoelectric focusing (IEF), we removed the excess albumin and IgG
from the bile samples. Using this approach, .80% of the albumin
was removed from each sample (Fig. 1B). The silver-stained gels of
crude bile and purified bile (albumin removal plus protein
precipitation) were compared. The total protein loss following
precipitation alone was less than 20%, as determined by the
control experiments (data not shown). Albumin was the only
protein removed in significant amounts; otherwise, the overall
protein pattern was unchanged following the purification (Fig. 1B).
A comprehensive analysis of the bile duct bile proteome
Bile samples from four choledocholithiasis patients who showed
no signs of cholangitis nor malignancy (i.e., an absence of clinical
and laboratory signs) or other biliary tract abnormalities were
analysed. A total of 1,500 mg of bile proteins (375 mg from each of
the four samples) were mixed and purified as outlined in the
Materials and Methods section. A total of 500 mg or 1 mg of the
purified proteins was separated using 2-D SDS-PAGE and stained
with colloidal Coomassie dye (Fig. 2A,B). All the visible protein
spots were selected and analysed by MS-MS Maldi-TOF mass
spectrometry. To identify all the proteins that were not separated
in the IEF step, a second sample of 50 mg of purified protein was
separated by 1-D SDS-PAGE only and the proteins were
determined by mass spectrometry (Fig. 1C). By combining these
methods, we were able to unambiguously identify 379 proteins
with a high Mascot score. Of the 379 identified proteins, 301 were
characterised in the Uniprot Knowledgebase (Table S1), and 78
were hypothetical, predicted, or otherwise not further defined
(Table S2). Furthermore, we identified 558 proteins with a Mascot
score ,100 and/or with only one uniquely identified peptide.
These proteins were considered to be identified with less certainty
and were therefore separated and included in the Supplemental
Material (Table S2, S3). Of these proteins, the most prominent
and abundant proteins on the 2-D gel were primarily found in the
plasma/serum in addition to the bile. By comparison, 130 of the
301 known proteins had been previously identified in proteomic
studies of the serum and plasma. We classified the bile proteins
according to the biological processes they have been identified as
performing and by their molecular function, predicted subcellular
localisation, and tissue expression. The majority of the bile
proteins were predicted to be cytosolic (124/301), secreted (100/
301), or plasma membrane-associated (42/301). Bile proteins
predicted to be associated with the nucleus or mitochondria were
uncommon (Fig. 1D). The biological processes associated with the
primarily identified known proteins included immune response
(62/301), metabolism (57/301), and cell homeostasis (57/301). For
23 of the 301 characterised proteins, the function was unknown or
could not be clearly classified (Fig. 1E). The most frequent
pathways proteins are involved in were Acute Phase Signaling (21/
301), Digestion and Absorption (17/301), Signal Transduction
(17/301), Inflammatory and Stress Response (15/301) and
Cytoskeletal Signaling (14/301). (Fig. 1F). In total 40 pathway
could be identified (Table S4). For 19 proteins the pathway they
are involved in could not be identified.
Biliary protein levels are associated with disease activity
in patients with PSC
Bile from the PSC patients (n=46) showed markedly elevated
biliary protein concentrations compared to controls (n=24)
(2726295 mg/ml vs. 1186410 mg/ml, respectively; p,0.001;
Fig. 3A), which was even more pronounced when normalised by
the bile-acid concentration (866131 mg/mmol vs. 666288 mg/
mmol, respectively; p,0.001; Fig. 3C). A comparison between the
PSC patients based on their endoscopic disease activity showed
that the biliary-protein content and the protein content normalised
by the BA concentration were both significantly elevated in the
high-disease-activity PSC patient group (n=19; 3726366 mg/ml
and 1246143 mg/mmol, respectively) compared to the low-
activity group (n=27; 2016213 mg/ml and 596117 mg/mmol,
respectively; p,0.05). Both of the groups had greater total biliary-
protein content and biliary-protein content normalised by the BA
concentration compared to the controls (Fig. 3B,D). If the PSC
patients were categorised by their Mayo risk scores (MRS), the
total and normalised protein contents were significantly different
between the low-MRS and intermediate-MRS patients (Fig. 3E,F).
The comparison of the protein expression profiles
identified marked upregulation of S100A9
To identify disease-dependent alterations in the relative
amounts of specific proteins, a subset of the protein spots on the
2-D gel was quantified using densitometry and normalised to
protein content, as outlined above (Fig. 4A,B). The expression
levels of S100A9 were significantly increased in the PSC patients
(Fig. 4C). The S100A9 expression was elevated by approximately
95-fold relative to the baseline serum proteins (0.0460.09
arbitrary units vs. 3.8364.43 arbitrary units, respectively;
p,0.005; n=6 controls and n=19 PSC patients). When
comparing the control patients to the patients with low- or high-
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29821Figure 1. Bile purification and identification of biliary proteins. (A) Comparison of serum (S), plasma(P), andbile duct-derived bile proteins(B)
from two choledocholithiasis patients demonstrates many similar expressed proteins; however, the protein composition differs between the serum and
bile samples. (B) Albumin and IgG depletion and purification for the crude bile duct-derived bile samples. The purification of the bile samples was
monitored using 1-D silver stained gels, and the crude bile samples (Lane 1) were compared to the precipitated samples depleted of albumin and IgG.
Thearrowindicatesthemarkedreductioninalbumin.(C) Amixtureofbilesamples wasseparatedby1-DGelelectrophoresis,cutintothedepictedslices
and analysed by mass spectrometry. The 301 identified proteins with a Mascot score .100 were classified according to reported subcellular localisation
(D), the biological processes in which they are involved (E) and the pathways the majority of proteins are involved (F).
doi:10.1371/journal.pone.0029821.g001
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29821Figure 2. 2-D SDS-PAGE analysis of purified bile. 2-D gels of biliary proteins. pH range of the first-dimension isoelectric focusing gel is shown at
the bottom, and the sizes of the molecular mass standards (in kDa) for the second dimension are indicated on the left. The proteins corresponding to
the spots on the gels (circled in blue) were identified by mass spectrometry. (A) 500 mg of protein was separated on a gradient from pH 3–11 (non-
linear). To identify less abundant proteins, (B), 1 mg of protein was separated; more prominent spots were excluded, and the less prominent spots
were identified by mass spectrometry.
doi:10.1371/journal.pone.0029821.g002
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137-fold, respectively (0.0460.09 vs. 2.8864.56 and 0.0460.09
vs. 5.8963.64, respectively; p,0.05 and p,0.005, respectively;
n=6 controls, n=13 low-activity PSC patients, and n=6 high-
activity PSC patients). The S100A9 expression was increased 2-
fold in patients with high disease activity (p,0.05) (Fig. 4D). When
the Mayo risk scores were compared, S100A9 was significantly
different between the patients with low and intermediate MRS
(Fig. 4E). A comparison of the pancreatic enzymes chymotrypsin-
ogen B and triacylglycerol lipase showed no significant differences
between the control and PSC patients or between the two PSC
subgroups. We validated these results in 37 samples from
additional patients (n=8 controls and n=29 PSC patients with
low disease activity) by measuring the total S100 protein
concentration in aspirated bile. In these samples, the total S100
levels were 0.3160.23 mg/l in the PSC group and 0.0860.05 mg/l
in the control group (p,0.001; Fig. 4F).
S100A9 expression analyses in brush cytology samples
The S100A9 mRNA expression levels were also analysed in the
brush cytology samples from the PSC patients with unclear
stenosis. The S100A9 mRNA expression was found to be
upregulated by approximately 30-fold in the brush cytology
samples from the PSC patients with high endoscopic disease
activity relative to those with low disease activity (3,01261998 vs.
102695, respectively; p,0.05; n=8; Fig. 4G).
The cytological analyses of the brush samples from the PSC
patients with low and high disease activities displayed inflamma-
tory cell infiltration and inflammatory alterations of epithelial,
which correlated with the S100A9 levels detected in the
corresponding bile samples (Fig. 4H,I)
Discussion
In this study, we identified nearly 400 proteins in bile duct-
derived bile of patients without inflammation and malignancy.
Furthermore, we demonstrated that bile protein expression
profiles are disease-dependent in PSC patients and that profile
alterations reflect changes at the epithelial level. Therefore, as a
complement to the significant data available on the lipid
composition of bile, the biliary protein expression profile
uncovered here provides new mechanistic insights into cholestatic
disease. These insights may have the potential to lead to new
therapeutic targets.
Bile-sample protein analysis is hampered by the overall protein
concentration in bile being low, and the low molecular weight
compounds, such as BAs, phospholipids, and bilirubin, are present
in high concentrations and strongly interfere with IEF, gel
electrophoresis, and further biochemical analyses. Protein consti-
tutes approximately 5% of the dry weight of bile [16] and is
derived from serum, hepatocytes, and bile duct epithelial cells
[17].
Using our purification method, we were able to identify the
components of the bile duct-derived bile proteome. Previous
studies focused on analysis of gallbladder bile or bile from patients
with hepatobiliary malignancy [18,19,20,21,22] [23,24]. In both
cases, these analyses would result in a bile proteome significantly
different from that of bile duct-derived bile in a non-malignant
setting. The physiological bile duct-derived bile proteome
established in the current study may serve as a standard of
reference for further studies and complements the data of the
previous studies. In addition, we identified 78 bile proteins whose
functions are not yet known. Proteins with a Mascot score of less
than 100, which are presented in the Supplemental Material
section, accounted for an additional 467 candidate bile proteins
and will be the focus of future studies. To assure specificity, we
included only proteins with a Mascot score greater than or equal
to 100 and with a minimum of two unique peptides.
The precise origin of individual bile proteins is unclear. We
detected only minor concentrations of cellular components from
the mitochondria, nucleus, and cytoskeleton. These findings
provide evidence that biliary proteins in bile duct-derived bile
are not cellular debris. Many of the proteins in bile, including
albumin, immunoglobulins, haptoglobin, haemoglobin subunits,
transferrin, fibrinogen, and components of the complement
system, are also found in human serum; their concentrations in
bile are approximately 0.2% of their serum concentrations [25].
Other bodily fluids, such as urine [26] and tears [27], also contain
serum proteins at minor concentrations relative to blood. Different
factors are responsible for the presence of serum proteins in bile
fluid. Due to the concentration gradient between the serum and
bile, serum proteins may pass through the tight junctions between
hepatocytes and biliary epithelial cells and enter the bile fluid [28].
Furthermore, large amounts of albumin, and possibly other serum
proteins, are secreted directly into bile by hepatocytes [29].
Transcytosis may contribute to the movement of proteins in bile,
and receptor-mediated protein endocytosis at the hepatocyte
sinusoidal membrane has been shown for IgA in rats [30].
Furthermore, the exocytosis of lysosomal enzymes and co-
transport of phospholipids have also been demonstrated for bile
[31]. Interestingly, the biliary protein content in PSC patients was
found to be associated with chronic inflammation and demon-
strated a positive correlation with the disease activity. This finding
was highlighted when the patients were categorised by their
endoscopic findings and by established Mayo risk score stratifica-
tions.
The S100A9 protein was originally discovered as an immuno-
logical protein in neutrophils and has more recently been
associated with several forms of human cancer and inflamma-
tion-associated carcinogenesis. When combined with S100A8,
S100A9 forms the heterodimeric protein calprotectin (S100A8/9),
which is expressed in nearly all the cells, tissues, and fluids of the
human body [32]. S100A8/9 appears to exhibit antimicrobial and
antiproliferative activities and may regulate inflammation, as
increased S100A8/9 concentrations were observed during the
acute-phase reaction. The S100A8/9 heterodimer is most likely
secreted by monocytes and granulocytes, and its extracellular
effects are mediated through the RAGE (receptor for advanced
glycation end products), a multiligand receptor of the immuno-
globulin family [32].
In the bile from the PSC patients, the S100A9 concentration
increased with disease activity and was significantly greater in the
Figure 3. Correlation between biliary proteins and disease activity in PSC patients. Bile from PSC patients showed a marked increase in
biliary protein content. (A) Box plots of the protein concentration per volume show a marked increase for the PSC patients. If the PSC patients were
classified based on disease activity, either by endoscopic findings (C) or by Mayo Risk score (E), the corresponding biliary protein concentrations
showed significantly greater concentrations in the patients with high PSC activity than in those with low activity. If the bile samples were normalised
by the bile-acid content, the results were similar (B, controls versus all the PSC patients; D, PSC patients classified by endoscopic findings; F, PSC
patients classified by Mayo Risk Score). Box plots of the protein concentration normalised by the BA concentration. (control=24, PSC=45, low
MRS=25, intermediate MRS=20; low endoscopic=26; high endoscopy activity=19; ns=not significant; *p,0.05; **p,0.005).
doi:10.1371/journal.pone.0029821.g003
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asis. Increased S100A9 levels have also been associated with a
variety of other inflammatory diseases. S100A8/9 overexpression
was first discovered in cystic fibrosis, but later studies have also
demonstrated elevated S100A8/9 levels in active chronic inflam-
matory bowel disease and in the synovial fluid of patients with
rheumatoid arthritis [32]. A potential positive role for S100A8/9
in dendritic cells has also been proposed in the context of primary
biliary cirrhosis pathogenesis [33]. Even though S100A8/9 is not
specific for a particular disease entity and its levels fluctuate
considerably between individual patients, it may nevertheless help
in identifying inflammatory processes in patients in the absence of
diagnostic clinical findings. Furthermore, recently published
clinical and experimental data suggest an important role for
changes in the expression and/or function of S100 proteins in
carcinogenesis [32,34].
Bile has the potential to serve as a surrogate substance for
further analysis; therefore, we performed experiments to char-
acterise bile and confirm its components at the cellular level. Bile
analysis is an attractive option for diseases confined to the biliary
epithelium and/or diseases that represent a non-homogeneous
distribution pattern in the liver. These include PSC and (early)
cholangiocarcinoma, as cells involved in these diseases are often
not easily accessed. As outlined above, therefore, bile is an
attractive integrative parameter for identifying either diagnostic
markers or immunologically-active substances. To determine
whether the changes in the bile-protein profiles were also exhibited
by the epithelial cells, we performed an analysis of the brush
cytology samples acquired during ERC. We found that both the
cytological analyses and quantitative real-time PCR analysis of the
S100A9 mRNA expression levels confirmed our results from the 2-
D gel comparison of the bile-protein samples. This result suggests
that our approach is generally feasible and that further studies
(e.g., determining changes in differentiation between PSC and
cholangiocarcinoma) are promising. Furthermore, it will be
interesting to correlate these findings with data from the ongoing
genome-wide association studies of PSC patients and in the
context of bicarbonate-mediated protection of the biliary epithe-
lium [35–36].
In conclusion, in the current study, we defined a proteome of
bile derived from the bile duct in a non-inflammatory and non-
malignant setting that could serve as a reference point for further
studies. Furthermore, we identified the biliary S100A9 level as a
marker for disease activity in PSC patients and confirmed these
findings at the cellular level by brush cytology samples. Therefore,
biliary sampling and the analysis of bile markers should be tested
as a routine diagnostic tool for patients with cholestatic liver
diseases.
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